Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Abemaciclib is an ATP-competitive, reversible kinase inhibitor selective for CDK4 and CDK6 that has shown antitumor activity as a single agent in hormone receptor positive (HR+) metastatic breast cancer in clinical trials. Here, we examined the mechanistic effects of abemaciclib treatment using in v...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Torres-Guzmán, Raquel, Calsina, Bruna, Hermoso, Ana, Baquero, Carmen, Alvarez, Beatriz, Amat, Joaquín, McNulty, Ann M., Gong, Xueqian, Boehnke, Karsten, Du, Jian, de Dios, Alfonso, Beckmann, Richard P., Buchanan, Sean, Lallena, María José
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642494/
https://ncbi.nlm.nih.gov/pubmed/29050219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17778
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados